Expanded Access to Investigational Drugs for Treatment Use: Questions and Answers

Why It Matters

Clarifying expanded‑access rules accelerates patient access to investigational therapies while reducing regulatory uncertainty for sponsors, impacting drug development timelines and compassionate‑use programs.

Key Takeaways

• Guidance answers FAQs on FDA expanded access regulations.
• Covers updates from 21st Century Cures and 2017 Reauthorization Acts.
• Provides step‑by‑step IND submission process for treatment use.
• Allows comments on guidance at any time via online or mail.
• Aims to streamline patient access to investigational therapies.

Pulse Analysis

The FDA’s expanded‑access program, codified in 21 CFR part 312 subpart I, lets patients with serious or life‑threatening conditions obtain investigational drugs outside clinical trials. First implemented in 2009, the pathway has grown in importance as more therapies target rare diseases and oncology. In June 2016, the agency released a comprehensive Q&A guidance, later updated in October 2017, to clarify procedural nuances that industry, physicians, and IRBs repeatedly questioned. By consolidating the most common inquiries, the document serves as a practical reference for navigating the regulatory landscape.

The guidance tackles several critical areas: eligibility criteria for patients, sponsor responsibilities, and the IND submission workflow required for treatment‑use requests. It also integrates provisions introduced by the 21st Century Cures Act and the FDA Reauthorization Act of 2017, which expanded patient‑focused drug development and mandated more transparent reporting. Notably, the document outlines how sponsors can request emergency use, obtain Institutional Review Board approval, and manage adverse‑event reporting, thereby reducing uncertainty that previously slowed access to promising therapies.

For pharmaceutical companies, the clarified rules translate into faster decision‑making and lower administrative overhead, enabling them to honor compassionate‑use commitments without jeopardizing ongoing trials. Physicians gain a clearer roadmap to advocate for eligible patients, while patients benefit from a more predictable pathway to potentially life‑saving treatments. The FDA encourages ongoing public comment, ensuring the guidance evolves with emerging science. As the pipeline of novel agents expands, stakeholders who adopt these best practices will be better positioned to balance safety, regulatory compliance, and timely patient access.